CoronaVac – Page 25 – Communicable Diseases Research

Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

브라질의 코로나 박 백신에서 P1 변이체에 의한 2 개의 예방 접종 후 SARS-COV-2 감염의 사례 연구

Case Reports

Published on 2021-06-262022-09-01
Journal: Viruses [Category] MERS, SARS, 변종, 임상, 진단,

CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk

Editorial

Published on 2021-06-232022-10-31
Journal: Clinics [Category] Coronavirus, SARS,

[키워드] anti-SARS-CoV-2 CoronaVac human milk IgA antibody induce
[DOI] 10.6061/clinics/2021/e3185 PMC 바로가기 [Article Type] Editorial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

60세 이상의 건강한 성인을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 임상 시험

Randomized Controlled Trial

Published on 2021-06-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] Adults Adverse reaction Adverse reactions age All participants Aluminium aluminium hydroxide antibody Antibody Response Antibody titre assigned baseline Beijing block Block randomisation China Chinese clinical trial CoronaVac COVID-19 COVID-19 vaccine Cutoff defined detectable development dose dose-escalation double-blind eight Endpoint enrolled groups healthy hydroxide immunogenicity inactivated injection injection site pain intervention group Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate morbidity morbidity and mortality Neutralising Antibodies neutralising antibody neutralising antibody titres occurred Older Older adults participant Participants Phase 1 Phase 2 phase 3 trial Placebo placebo group placebo-controlled positive primary immunogenicity Program random assignment randomised Randomly receive Registered reported research and development Safe Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Events Seroconversion seroconversion rate seronegative seropositive Seven severity technology the disease the placebo group titre Tolerability treatment allocation trial protocol vaccination Vaccine virus
[DOI] 10.1016/S1473-3099(20)30987-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

비활성화 및 RBD-서브유닛 백신에 의해 유발된 순환 SARS-CoV-2 변이체에 대한 체액 면역 반응

Article

Published on 2021-05-212022-09-11
Journal: Cell Research [Category] Fulltext, SARS, 변종, 진단,

[키워드] (inactivated vaccine) 501Y.V2 administration anti-RBD antibody antigenic B.1.351 boost caused circulating SARS-CoV-2 variant circulating SARS-CoV-2 variants combating Combination comparable conformation Contact convalescent CoronaVac Cryoelectron microscopy disrupt dominant E484K Effect elicited humoral immune response Immune escape immune response immunology inactivated Inactivated vaccine induce K417N leads less majority mononuclear cell mononuclear cells Mutation mutations N-terminal domain NAb NAbs natural infection neutralization neutralization activity Neutralizing activity Neutralizing antibodies neutralizing antibody NTD Peripheral blood Peripheral blood mononuclear cells plasma polar RBD RBD variants receptor Receptor-binding domain reduced reduction regions respond SARS-CoV-2 variant SARS-CoV-2 variants second dose Sequencing single-cell the receptor-binding domain Tolerance Vaccine vaccinee vaccinees variants VDJ X-ray crystallography ZF2001
[DOI] 10.1038/s41422-021-00514-9 PMC 바로가기 [Article Type] Article

An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times

Review

Published on 2021-04-272022-10-28
Journal: Vaccines [Category] COVID-19,

SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines

Review

Published on 2021-03-052022-10-28
Journal: Vaccines [Category] COVID-19,

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

18~59세의 건강한 성인을 대상으로 한 비활성화된 SARS-CoV-2 백신의 안전성, 내약성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1/2상 임상 시험

Clinical Trial

Published on 2021-02-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단,

[키워드] 1:1 acute respiratory syndrome Adverse reaction allergic assigned axillary temperature Beijing Block randomisation Cell chamber China Chinese clinical trial Cohort cohorts Community Corning CoronaVac coronavirus COVID-19 COVID-19 pandemic development diluent dose dose-escalating manner double-blind Efficacy Endpoint enrolled FIVE healthy High-dose hydroxide immunogenic inactivated Inactivated vaccine incidence Infection injection investigated investigators Jiangsu Laboratory live SARS-CoV-2 low dose low-dose morbidity and mortality neutralising antibody nine outcome participant per-protocol population phase 1 trial phase 2 trial Phase 3 trials Placebo placebo-controlled produced Program randomisation randomised Randomly receive recruited Registered Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science separated Seroconversion seroconversion rate Seven Sinovac Life Sciences study drug suggested Taking technology the placebo group Tolerability treatment allocation Trial vaccination vaccination schedule Vaccine was done were excluded were given
[DOI] 10.1016/S1473-3099(20)30843-4 PMC 바로가기 [Article Type] Clinical Trial

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

COVID-19 백신 개발의 진행 상황 및 과제 검토

Review

Published on 2020-10-142022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 신약개발, 진단, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition affecting anticipated ARDS AstraZeneca Asymptomatic AZD1222 cause challenge China claimed clinical trial clinical trials CoronaVac coronavirus Coverage COVID-19 COVID-19 pandemic death develop Developing DNA vaccine effective Efficacy effort eight focus global pandemic hygiene immunogenic immunological implication inactivated virus particle vaccine individual Infectious disease International life measure Moderna mRNA-1273 Neutralizing antibodies non-replication viral vector vaccine Novel coronavirus Phase 1 Pneumonia potential limitation potential limitations present Progress PROTECT referred to Repurposed drugs required respiratory respiratory distress Respiratory distress syndrome review RNA vaccine SARS-CoV-2 SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus Sinovac social distancing Spread Stage Symptom syndrome Vaccine vaccine candidate vaccine candidates Vaccine development vaccine platform Vaccines vulnerable population Wuhan
[DOI] 10.3389/fimmu.2020.585354 PMC 바로가기 [Article Type] Review